PMID- 27835868
OWN - NLM
STAT- MEDLINE
DCOM- 20180223
LR  - 20221207
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 51
DP  - 2016 Dec 20
TI  - Clinical data from the real world: efficacy of Crizotinib in Chinese patients 
      with advanced ALK-rearranged non-small cell lung cancer and brain metastases.
PG  - 84666-84674
LID - 10.18632/oncotarget.13179 [doi]
AB  - Brain metastasis in non small cell lung cancer (NSCLC) patients is often 
      considered as a terminal stage of advanced disease. Crizotinib is a 
      small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients. 
      Herein, we conducted a retrospective study to explore how Crizotinib affects the 
      control of brain metastases and the overall prognosis in advanced ALK-rearranged 
      NSCLC patients with brain metastases in Chinese population. A total of 34 
      patients were enrolled, of whom 20 (58.8%) patients had baseline brain metastases 
      before Crizotinib treatment. Among patients with brain metastases before 
      Crizotinib, overall survival (OS) after brain metastases was significantly longer 
      than that of patients with brain metastases after Crizotinib (median OS, not 
      reached vs. 10.3 months, respectively, p = 0.001). There was also a significant 
      difference in systemic progression-free survival (PFS) between patients 
      developing brain metastases before and after Crizotinib treatment (21.2 months 
      vs. 13.9 months, p = 0.003). In conclusion, ALK-rearranged NSCLC patients with 
      brain metastases before Crizotinib may benefit more from Crizotinib than those 
      developing brain metastases during Crizotinib treatment.
FAU - Xing, Puyuan
AU  - Xing P
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
FAU - Wang, Shouzheng
AU  - Wang S
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
FAU - Hao, Xuezhi
AU  - Hao X
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
FAU - Zhang, Tongtong
AU  - Zhang T
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
FAU - Li, Junling
AU  - Li J
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Antineoplastic Agents/*therapeutic use
MH  - Asian People
MH  - Brain Neoplasms/*drug therapy/mortality/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/secondary
MH  - China
MH  - Crizotinib
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyrazoles/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Young Adult
PMC - PMC5356690
OTO - NOTNLM
OT  - NSCLC
OT  - brain metastasis
OT  - chinese
OT  - crizotinib
OT  - real world
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2016/11/12 06:00
MHDA- 2018/02/24 06:00
PMCR- 2016/12/20
CRDT- 2016/11/12 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/10/28 00:00 [accepted]
PHST- 2016/11/12 06:00 [pubmed]
PHST- 2018/02/24 06:00 [medline]
PHST- 2016/11/12 06:00 [entrez]
PHST- 2016/12/20 00:00 [pmc-release]
AID - 13179 [pii]
AID - 10.18632/oncotarget.13179 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Dec 20;7(51):84666-84674. doi: 10.18632/oncotarget.13179.